SEMICONDUCTOR ANALYTICS
Click category or weSRCH domain below to read news from each weSRCH domain
High Tech :- Business, Consumer, Displays, IT, Mobile, Photo, Semiconductors
Medicine :- Biology, Biotech/Pharma, Equipment, Imaging, Implants, Practice Mngmnt, Therapy, Veterinary
Green Tech :- Battery & Fuel, Biomass, Environmental, Fossil/Nuclear, Lighting, Solar, Trans, Wind/Water/Geo
Business :- Companies, Entrepreneurial, IP/Law, Leadership & Strategy, Management, Sales & Marketing, Social Innovation

Latest News, Top News, Breaking News


     

    Corbus Pharmaceuticals Can Hit New Highs By Year's End - Seeking Alpha

      Corbus Pharmaceuticals (NASDAQ:CRBP) has made waves recently for its cystic fibrosis (CF) Phase II data for Anabasum, but it is the upcoming data on the same drug for two other indications--systemic sclerosis and derm Save |  Share  Email 23rd Jun 2017 
     

    BRIEF-China Regenerative Medicine International says during period between 30 May & 6 June, co received notices ... - Reuters

      Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world n Save |  Share  Email 23rd Jun 2017 
     

    Bioengineers create more durable, versatile wearable for diabetes monitoring - EurekAlert (press release)

      EurekAlert (press release) IMAGE: Researchers at the University of Texas at Dallas have developed a wearable diagnostic biosensor that can detect three interconnected, diabetes-related compounds -- Save |  Share  Email 23rd Jun 2017 
     

    Type 1 diabetes: Almost half of patients produce insulin - Medical News Today

      Medical News Today Researchers from Uppsala University in Sweden found that nearly half of patients who had been living with diabetes for more than 10 years produced some insulin. What is more, these insulin-producing patients Save |  Share  Email 23rd Jun 2017 
     

    CALMing Insights That Make a SONIC Boom - Medscape

      Medscape When it comes to clinical endpoints, we have recognized for several years that symptoms do not correlate well with endoscopic or other "biologic" targets, such as C-reactive protein or fecal calprotectin. Symptom-directed therapies ma Save |  Share  Email 23rd Jun 2017 
     

    Diabetes is manageable-unless you live in Syria - Rescue

      Rescue Diabetes can be managed. It's a chronic disease, marked by the body's inability to either produce or effectively use insulin to control blood sugar levels. The key to staying healthy? Maintaining consistent blood sugar over time wit Save |  Share  Email 23rd Jun 2017 
     

    Better Know a Marijuana Stock: Arena Pharmaceuticals - Madison.com

      Madison.com Unlike GW Pharmaceuticals and Zynerba Pharmaceuticals, which rely on cannabinoid-based medicines to fill out the entirety of their drug-development pipelines, Arena Pharmaceuticals is one of the drug developers like Insys The Save |  Share  Email 23rd Jun 2017 
     

    Treatment Options: Biologic Medication Entyvio Is Next for Me - IBD News Today

      IBD News Today In a single article outside of my usual pattern of writing a series, I wanted to focus more on the biologic drugs and medications offered to Crohn's disease and ulcerative colitis patients, speci Save |  Share  Email 23rd Jun 2017 
     

    Oral Insulin May Delay Type 1 Diabetes Onset in 'Responders' - Medscape

      Medscape SAN DIEGO - Close relatives of people with type 1 diabetes who had certain autoantibodies believed to put them at high risk of progression to clinical type 1 diabetes did not benefit from taking oral insu Save |  Share  Email 23rd Jun 2017 
     

    Friday's Vital Data: Advanced Micro Devices, Inc. (AMD), Valeant Pharmaceuticals Intl Inc (VRX) and BlackBerry Ltd ... - Investorplace.com

      Investorplace.com Despite a string of setbacks this week, the Dow Jones Industrial Average is still on track to post gains for the fifth straight week. Oil remai Save |  Share  Email 23rd Jun 2017 
     

    EU regulators greenlight US biotech Aveo's kidney cancer drug - Reuters

      Channel NewsAsia European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing th Save |  Share  Email 23rd Jun 2017 
     

    Eton Pharmaceuticals Names Sean Brynjelsen Chief Executive ... - PR Newswire (press release)

      CHICAGO, June 23, 2017 /PRNewswire/ -- Eton Pharmaceuticals, Inc., a development stage pharmaceutical company, today announced the hiring of Sean ...and more » Save |  Share  Email 23rd Jun 2017 
     

    3 Biotech Stocks for Enterprising Investors - Motley Fool

      Motley Fool Biotech stocks are a natural area of exploration for aggressive investors with high expectations for their stocks. After all, this high-growth industry is chock-full of novel growth platforms, some of which can be challenging to under Save |  Share  Email 23rd Jun 2017 
     

    AVEO Oncology (AVEO) Announces Positive CHMP Opinion for Tivozanib as Treatment of Advanced Renal Cell ... - StreetInsider.com

      ... growth factor (VEGF) inhibitors are the standard of care treatment for advanced RCC in Europe, however, patients on current treatments can often experience significant side Save |  Share  Email 23rd Jun 2017 
     

    Diabetes moving from affliction of affluent countries to a global problem - Medical Xpress

      The number of people with diabetes has quadrupled from 1980 to 2014, and 415 million adults in the world now have diabetes, according to Rollins researchers. Globally, it was estimated that diabetes accounted for Save |  Share  Email 23rd Jun 2017 
     

    EMA committee gives Samsung Bioepis nod for Humira biosimilar Imraldi - BioPharma-Reporter.com

      BioPharma-Reporter.com The EMA has recommended the approval of Samsung Bioepis' adalimumab biosimilar, placing the firm on the brink of having three anti-TNF inhibitors in Europe. The European Medicines Ag Save |  Share  Email 23rd Jun 2017 
     

    Pfizer gets CRL on Epogen biosimilar from FDA - Pharmaceutical Business Review

      The United States Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Pfizer in connection with its biosimilar candidate to Amgen's anemia drug Epogen (epoetin alfa). According to Save |  Share  Email 23rd Jun 2017 
     

    Novartis' heart drug canakinumab meets primary endpoint in phase III study - Pharmaceutical Business Review

      Pharmaceutical Business Review Novartis' heart drug ACZ885 (canakinumab) has met primary endpoint in the global phase III Canakinumab anti-inflammatory thrombosis outcomes (Cantos) study. Save |  Share  Email 23rd Jun 2017 
     

    Diabetes Devices Market Is Predicted To Hit USD 28.2 Bn By 2022, Credence Research - Technorati

      Technorati According to the latest report published by Credence Research, Inc. "Diabetes Devices Market Growth, Future Prospects and Competitive Analysis, 2016-2022,? the global diabetes devices Save |  Share  Email 23rd Jun 2017 
     

    Biologic Response Modifiers Market Future Demand and Growth ... - Medgadget (blog)

      Report Monitor Present's United States Biologic Response Modifiers Market 2017 Industry Trend Enhances The Decision Making Capabilities And Helps To ...and more » Save |  Share  Email 22nd Jun 2017 
     
     
    Maxims of Tech: Rules of Engagement for a Fast Changing Environment